Tamibarotene

CHEMBL25202 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
351.4 g/mol
LogP
5.4
Phase
4

Tamibarotene is a synthetic retinoic acid receptor alpha (RARα) agonist that promotes differentiation of leukemic blast cells, particularly in acute promyelocytic leukemia (APL) and is being studied for other hematologic malignancies. It is more selective for RARα than all-trans retinoic acid (ATRA), with potentially improved efficacy and tolerability in refractory APL. Research has also explored its role in Alzheimer's disease through modulation of neuroinflammatory pathways.

分子量

351.4000 g/mol

LogP

5.40

TPSA

66.40 Ų

リピンスキーの五則

適合

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21

InChI

InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)

Molecular Formula

C22H25NO3

HBD / HBA

2 / 3

回転可能結合数

3

重原子数

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Tamibarotene is a synthetic retinoic acid receptor alpha (RARα) agonist that promotes differentiation of leukemic blast cells, particularly in acute promyelocytic leukemia (APL) and is being studied for other hematologic malignancies. It is more selective for RARα than all-trans retinoic acid (ATRA), with potentially improved efficacy and tolerability in refractory APL. Research has also explored its role in Alzheimer's disease through modulation of neuroinflammatory pathways.

Yes, Tamibarotene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL25202. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 108143. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.